Moxifloxacin (moxifloxacin HCl)

Ophthalmic Antibacterials Ophthalmic (Eye) Drops

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Moxifloxacin is a fluoroquinolone anti-infective agent.

Moxifloxacin is a fluoroquinolone anti-infective agent. Like other commercially available fluoroquinolones, moxifloxacin contains a fluorine at the C-6 position of the quinolone nucleus. Moxifloxacin, like gatifloxacin, contains an 8-methoxy group and has been termed an 8-methoxy fluoroquinolone.

Like other fluoroquinolones, moxifloxacin inhibits DNA synthesis in susceptible organisms via inhibition of type II DNA topoisomerases (DNA gyrase, topoisomerase IV).

Moxifloxacin is active in vitro and in vivo in conjunctival infections against some gram-positive bacteria, including Staphylococcus (S. aureus, S. arlettae, S. capitis, S. epidermidis, S. haemolyticus, S. hominis, S. saprophyticus, S. warneri ), Streptococcus (S. mitis, S. parasanguinis, S. pneumoniae, viridans streptococci ), Enterococcus faecalis, Aerococcus viridans, Corynebacterium (C. macginleyi), Micrococcus luteus, and Propionibacterium acnes.

Moxifloxacin also is active in vitro and in vivo in conjunctival infections against some gram-negative bacteria, including Acinetobacter lwoffii, Escherichia coli, Haemophilus influenzae, H. parainfluenzae, and Klebsiella pneumoniae. The drug also is active against Chlamydia trachomatis.

Cross-resistance can occur between moxifloxacin and other fluoroquinolones.

For the topical treatment of conjunctivitis caused by susceptible bacteria, moxifloxacin hydrochloride is commercially available as aqueous ophthalmic solutions containing 5 mg of moxifloxacin per mL. Moxifloxacin 0.5% ophthalmic solution (Moxeza(R)) is isotonic (osmolality of 300-370 mOsm/kg) and has a pH of approximately 7.4. Moxifloxacin 0.5% ophthalmic solution (Vigamox(R)) is isotonic (osmolality of 290 mOsm/kg) and has a pH of approximately 6.8.

Following topical application of moxifloxacin 0.5% ophthalmic solution to the eye, the drug is absorbed systemically and low moxifloxacin concentrations are attained in plasma. In a study in healthy adults using moxifloxacin 0.5% ophthalmic solution (Moxeza(R)), multiple, bilateral, topical ocular doses of the ophthalmic solution were applied twice daily for 4 days and resulted in peak plasma concentrations of moxifloxacin that were approximately 0.02% of those reported with usual dosages of oral moxifloxacin. In a study in healthy adults using moxifloxacin 0.5% ophthalmic solution (Vigamox(R)), bilateral topical doses of the ophthalmic solution were applied 3 times daily for 5 days and resulted in mean steady-state peak plasma concentrations and estimated daily exposure (determined by area under the plasma concentration-time curve (AUC)) 1600 and 1000 times lower, respectively, than values reported with usual dosages of oral moxifloxacin.

The half-life of systemically absorbed moxifloxacin is approximately 13 hours.

USES: This medication is a quinolone antibiotic used for eye infections.

Generic name: moxifloxacin HCl
Pronunciation: (mox-ih-FLOX-uh-sin)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Moxifloxacin

Intelligence content is not available yet.

Indications

The following indications are listed for Moxifloxacin:

  • Bacterial Conjunctivitis

Also known as: Inflammation Of The Conjunctiva Due To Bacteria.

Dosing

Moxifloxacin is commercially available for topical ophthalmic administration as moxifloxacin hydrochloride; dosage is expressed in terms of moxifloxacin.

Drug interactions

No formal drug interaction studies have been performed using moxifloxacin 0.5% ophthalmic solution.

In vitro studies indicate that moxifloxacin does not inhibit cytochrome P-450 (CYP) isoenzymes 1A2, 2C9, C19, 2D6, or 3A4; moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these CYP isoenzymes.

Contraindications

Moxifloxacin 0.5% ophthalmic solution is contraindicated in patients with known hypersensitivity to moxifloxacin, other quinolones, or any component in the formulation.

Adverse reactions

Moxifloxacin 0.5% ophthalmic solution (Moxeza(R)): Adverse effects reported in 1-2% of patients include eye irritation, pyrexia, and conjunctivitis.

Moxifloxacin 0.5% ophthalmic solution (Vigamox(R)): Adverse effects reported in approximately 1-6% of patients include conjunctivitis, decreased visual acuity, ocular dryness, keratitis, ocular discomfort/pain/pruritus, ocular hyperemia, subconjunctival hemorrhage, and tearing. Adverse systemic effects reported in approximately 1-4% of patients include fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

Precautions

No enhanced messaging available.

ICD codes

CodeTypeDescription
Bacterial conjunctivitis
H10.02ICD10CMOther mucopurulent conjunctivitis
H10.021ICD10CMOther mucopurulent conjunctivitis, right eye
H10.022ICD10CMOther mucopurulent conjunctivitis, left eye
H10.023ICD10CMOther mucopurulent conjunctivitis, bilateral
H10.029ICD10CMOther mucopurulent conjunctivitis, unspecified eye
H10.3ICD10CMUnspecified acute conjunctivitis
H10.30ICD10CMUnspecified acute conjunctivitis, unspecified eye
H10.31ICD10CMUnspecified acute conjunctivitis, right eye
H10.32ICD10CMUnspecified acute conjunctivitis, left eye
H10.33ICD10CMUnspecified acute conjunctivitis, bilateral

ICD code information from First Databank (FDB).

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data